Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts

0
87

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock rose 88.76% from a year ago, while it registered a 62.32% increase year-to-date. Based on consensus, Wall Street analysts have assigned a moderate buy rating to Intellia Therapeutics stock, with an average price target of $21.25.

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

In a Securities and Exchange Commission (SEC) filing dated April 10, Intellia Therapeutics reported that its Board adopted amendments to the company’s Third Amended and Restated By-laws on April 7. Under the Fourth Amended and Restated By-laws, the company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the company to notify the…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here